Caris Life Sciences Adds Two AI Signatures Predicting Brain Metastases in Breast, Lung Cancer
Caris Life Sciences added two Caris AI Insights signatures to its Caris Molecular Tumor Board Report, raising its total proprietary AI insights to seven and predicting brain metastases risk in breast and lung cancer patients. These signatures were trained on 12,994 NSCLC and 3,371 breast cancer cases.
1. Introduction of AI Signatures
Caris introduced two new AI signatures predicting brain metastases risk in breast cancer and non-small cell lung cancer, increasing its proprietary AI insights to seven. These signatures are available at no extra cost within the Caris Molecular Tumor Board Report when ordering the MI Cancer Seek assay.
2. Training Data and Methodology
The brain metastases signatures were developed using a dataset of 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes. Personalized predictive scores are generated from whole exome and transcriptome sequencing data and visualized via Kaplan-Meier curves.
3. Clinical and Commercial Implications
By identifying patients at elevated metastasis risk, these insights enable clinicians to shift from passive surveillance to proactive monitoring. The enhancement could drive broader adoption of the FDA-approved MI Cancer Seek assay and strengthen Caris’s precision oncology platform.